The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division, are expanding their long-standing collaboration with the development of two blood-stage malaria vaccine candidates for Phase I/II clinical trials.  

Since 2016, the collaboration has delivered five vaccine candidates and will now actively progress the manufacture of R78C and RH5.1 for the University’s Draper Lab, based at the Department of Paediatrics. 

ReciBioPharm initially produced both the drug substance and drug product for R78C and is now handling large scale fill and finish activities to meet increased vial demand for ongoing trials.  

Additionally, RH5.1 is now being fully produced by ReciBiopharm, including drug substance, drug product and large-scale fill and finish. 

“This collaboration with ReciBioPharm has been instrumental in accelerating the development of our malaria vaccine portfolio,” said Simon Draper, Professor of Vaccinology and Translational Medicine at the University of Oxford, and Group Leader of the Draper Lab. “With numerous malaria vaccine candidates now developed or in active development, this partnership plays a critical role in advancing innovative solutions aimed at reducing the global burden of malaria, and supports our shared mission to eradicate malaria altogether.” 

Globally, malaria continues to pose a significant health threat. According to the World Health Organisation’s World Malaria Report 2023, there was an estimated 249 million cases of malaria worldwide in 2022, resulting in 608,000 deaths. 

Greg Behar, CEO of Recipharm, added: “We’re proud to deepen our collaboration with the University of Oxford on such a critical global health challenge. Our ability to deliver drug substance and drug product for larger scales under GMP conditions makes us a strong partner for accelerating vaccine candidates from lab to clinic. Together, we’re advancing science with the potential to save millions of lives.”

Diana Spencer, Senior Digital Content Editor, DDW